Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor- and HER2-Positive Metastatic Breast Cancer | Zendy

Thomas E. Delea | Zendy; Carol Hawkes | Zendy; Mayur M. Amonkar | Zendy; Konstantinos Lykopoulos | Zendy; Stephen Johnston | Zendy

Open Access

Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor- and HER2-Positive Metastatic Breast Cancer

Author(s) -

Thomas E. Delea,

Carol Hawkes,

Mayur M. Amonkar,

Konstantinos Lykopoulos,

Stephen Johnston

Publication year - 2013

Publication title -

breast care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.767

H-Index - 30

eISSN - 1661-3805

pISSN - 1661-3791

DOI - 10.1159/000357316

Subject(s) - medicine , lapatinib , letrozole , breast cancer , oncology , anastrozole , aromatase inhibitor , metastatic breast cancer , gynecology , trastuzumab , cancer , aromatase

In the EGF30008 and TAnDEM (TrAstuzumab in Dual HER2 ER-positive Metastatic breast cancer) trials, anti-HER2 therapy plus an aromatase inhibitor (lapatinib + letrozole (LAP + LET) and trastuzumb + anastrozole (TZ + ANA), respectively) improved time to progression versus aromatase inhibitor monotherapy (LET and ANA, respectively) in post-menopausal women with previously untreated hormone receptor-positive (HR+) and HER2-positive (HER2+) metastatic breast cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research